The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Healthcare resource utilization in first-line immunotherapies for patients with metastatic melanoma.
 
Frank Xiaoqing Liu
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Andrew Klink
Employment - Cardinal Health
Stock and Other Ownership Interests - Cardinal Health
 
Bruce A. Feinberg
No Relationships to Disclose
 
Sama Ahsan
Employment - Merck Sharp & Dohme; Merck Sharp & Dohme (I)
Research Funding - Merck Sharp & Dohme; Merck Sharp & Dohme (I)
Patents, Royalties, Other Intellectual Property - Johns Hopkins Hospital
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Merck Sharp & Dohme (I)
 
Damion Nero
Employment - Cardinal Health; Cardinal Health
Stock and Other Ownership Interests - Megellan Health
Consulting or Advisory Role - Cardinal Health
Research Funding - Cardinal Health
 
Bartosz Chmielowski
Consulting or Advisory Role - Array BioPharma; Biothera; Bristol-Myers Squibb; Compugen; Genentech/Roche; HUYA Bioscience International; Iovance Biotherapeutics; Janssen; Merck; Novartis; Regeneron
Speakers' Bureau - Genentech/Roche; Janssen Oncology
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly/ImClone (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Biothera; Bristol-Myers Squibb; Compugen; Genentech/Roche; HUYA Bioscience International; Iovance Biotherapeutics; Janssen; Regeneron